GPs urged to help improve patient safety


The DSRU had coverage in the BMJ last week following the issue of the press release below. The article is available to BMJ subscribers here. "The DSRU is calling on GPs to help improve patient safety by providing vital information on possible adverse drug reactions. DSRU conducts Post Authorisation Safety Studies (PASS) in which the safety of newly licensed drugs is monitored using its own bespoke data collection methodology, known as Modified Prescription Event Monitoring (MPEM). This allows DSRU direct access to GPs to request information about any events experienced by patients after they’ve been prescribed a specific drug. DSRU collates [...]

GPs urged to help improve patient safety2019-11-05T14:52:59+00:00

DSRU team at RCGP Annual Conference!


The DSRU team is delighted to be at the Annual Conference of the Royal College of General Practitioners (RCGP) in Liverpool. Our medics are on hand at our booth in the exhibition to explain the vital role that GPs have played in our work to monitor prescription medicines for side effects. The team will also be providing delegates with information about our popular GP Masterclass in Effective Prescribing, which will take place on 13th November at the RCGP in London. The Masterclass has booked up quickly but there are a few places left.

DSRU team at RCGP Annual Conference!2019-10-25T12:33:36+00:00

Improving detection of adverse drug reactions


DSRU Director, Professor Saad Shakir, attended a three day meeting in Erice in Sicily on “Improving the Detection Analysis and Reporting Harms in Medicines”. The meeting was organised by the Uppsala Monitoring Centre and the Centre for Evidence Based Medicine in Oxford. The areas addressed at the meeting were the problems and proposed solutions for monitoring adverse drug reactions in clinical trials, the problems and proposed solutions for postmarketing pharmacovigilance and the problems and possible solutions for communications of drug safety. Professor Shakir chaired the session and led the discussion on the proposed solutions for postmarketing pharmacovigilance. He said that a [...]

Improving detection of adverse drug reactions2019-10-14T09:34:44+00:00

Is the UK facing its own opioid crisis?


Our Principal Research Fellow, Vicki Osborne, writes:   The opioid crisis in the US is well known and the subject of much debate and media coverage; overdoses involving opioids contributed to over two thirds (67.8%) of overdose deaths in the US in 2017 alone, with 47,600 deaths in total (1,2). Currently, 175 Americans die daily from drug overdoses and the majority of these involve opioids (3). In the UK, we have generally not seen the same levels of use which would cause concern in past years, though it would be complacent to assume that we do not have an issue. According [...]

Is the UK facing its own opioid crisis?2019-10-09T10:25:41+00:00

Expanding the reach of pharmacovigilance education with the Royal Pharmaceutical Society


The DSRU is delighted to be collaborating with the Royal Pharmaceutical Society to deliver two new training days. The courses are designed to introduce the core concepts of the field of drug safety (pharmacovigilance) as well as provide insights into the many career options available. Thinking about a career in the pharmaceutical industry? - Monday 18th November at the Royal Pharmaceutical Society, London Do you know anyone looking to kick start their career in drug safety? This collaborative course is aimed at anyone with an interest in pharmacovigilance and related job roles, no previous experience required. Delegates will be introduced to: [...]

Expanding the reach of pharmacovigilance education with the Royal Pharmaceutical Society2019-10-08T09:15:01+00:00

DSRU Consultancy: world class science at a not for profit price!


DSRU Consultancy has a small flexible team of epidemiologists, clinicians and pharmacists. Watch this short video to find out how DSRU Consultancy provides advice in pharmacoepidemiology, pharmacovigilance, risk minimisation and risk management. We can provide one-off or ongoing advice or we may give advice that leads to provision of a full study service. We also provide a special consultation service to smaller companies. The initial consultation is free! Watch this video to find out more or get in touch to discuss your enquiry (with no commitment): Dr Liz Lynn, Head of Scientific & Educational Development,

DSRU Consultancy: world class science at a not for profit price!2019-09-24T11:06:29+00:00

Success of Big Data for Pharmacovigilance Conference!


The DSRU’s Second Conference on Big Data for Pharmacovigilance has been a great success. Delegates from regulatory bodies, the pharmaceutical industry and academia have heard presentations from high calibre speakers, examining the challenges and opportunities for use of big data sources for the benefit of pharmacovigilance. Gianluca Trifirò from the University of Messina set the scene with an overview of the current status of big data in pharmacovigilance, including developments since our first Conference on Big Data for Pharmacovigilance in 2018. Niklas Noren from the Uppsala Monitoring Centre detailed some lessons learned in developing and deploying machine learning for pharmacovigilance, including [...]

Success of Big Data for Pharmacovigilance Conference!2019-09-13T12:04:15+00:00

The DSRU is at ICPE in Philadelphia!


The DSRU team is attending the International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) in Philadelphia. Come and meet our team at booth 204, where you can find out about our hospital PASS studies, our CPRD studies and DSRU Consulting. Find out about our research from our posters: Monday 26th August Characterisation of Drug Interaction Related Signals Leading to EU Regulatory Action and a Methodological Review of Novel Drug Interaction Signal Detection Methods in the Post-Marketing Setting D Roy, L Hazell, V Osborne, S Shakir Impact Analyses of European Pharmacovigilance Interventions on Public Health Burden S Lane, E Lynn, J [...]

The DSRU is at ICPE in Philadelphia!2019-08-27T21:47:00+00:00

Big Data for Pharmacovigilance: looking forward to our 2nd conference!


Our second conference on Big Data for Pharmacovigilance takes place in September in London. We have an impressive line-up of speakers who will examine the use of Big Data from many perspectives.  Highlights include: John Rigg, IQVIA: Realising the full potential of artificial intelligence in big populations Andrew Bate, Pfizer: Routine and emerging Big Data Strategies for Real World Evidence generation Andrew Roddam, GSK: Linking genetic information with clinical data Vassilis Koutkias, Centre for Research & Technology Hellas: OpenPVSignal, a tool for electronic exploration of signal reports Eva-Lisa Meldau, UMC: De-identification: use of natural language processing to remove patient identifiers from [...]

Big Data for Pharmacovigilance: looking forward to our 2nd conference!2019-08-02T12:19:36+00:00

The importance of recording brand and batch numbers of prescribed biologic medicines


In 2017-18, the NHS saved over £200 million by using more biosimilar medicines1. In 2018, NHS England announced plans to increase the uptake of biosimilars with the aim to save up to £300m a year by 20211. Generic versions of small molecule medicines can be considered chemically identical to the original branded version. A biosimilar is, in principle, the biologic equivalent of a generic drug. However because these are large complex molecules, often produced by living cells, a biosimilar is not regarded as identical to the original biologic drug. The manufacturing process of a biosimilar is very complex, so a lot [...]

The importance of recording brand and batch numbers of prescribed biologic medicines2019-07-26T11:36:38+00:00

Contact Info

Drug Safety Research Unit Bursledon Hall, Blundell Lane, Southampton, SO31 1AA, U.K.

Phone: +44 (0)23 80 40 86 00

Recent Posts